Analysts Offer Predictions for HRMY FY2026 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Harmony Biosciences in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will post earnings of $3.21 per share for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share.

Several other research analysts have also recently weighed in on HRMY. UBS Group lowered their target price on Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Monday, April 28th. Mizuho boosted their target price on Harmony Biosciences from $44.00 to $48.00 and gave the company an “outperform” rating in a research report on Thursday, May 15th. Oppenheimer assumed coverage on Harmony Biosciences in a research report on Monday, June 2nd. They issued an “outperform” rating and a $61.00 target price on the stock. Needham & Company LLC restated a “buy” rating and issued a $49.00 price target on shares of Harmony Biosciences in a research note on Tuesday, May 6th. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Harmony Biosciences currently has a consensus rating of “Buy” and an average target price of $53.00.

Harmony Biosciences Stock Performance

Shares of HRMY opened at $35.14 on Wednesday. The stock has a fifty day moving average price of $32.04 and a 200-day moving average price of $34.10. The firm has a market cap of $2.02 billion, a PE ratio of 16.65, a P/E/G ratio of 0.47 and a beta of 0.87. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences has a 12 month low of $26.47 and a 12 month high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, May 6th. The company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.19. The firm had revenue of $184.73 million for the quarter, compared to analysts’ expectations of $184.26 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company’s quarterly revenue was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.67 earnings per share.

Institutional Investors Weigh In On Harmony Biosciences

Several hedge funds have recently made changes to their positions in HRMY. Financial Management Professionals Inc. acquired a new stake in shares of Harmony Biosciences during the first quarter worth about $29,000. Brooklyn Investment Group boosted its stake in shares of Harmony Biosciences by 1,031.9% during the first quarter. Brooklyn Investment Group now owns 1,064 shares of the company’s stock worth $35,000 after buying an additional 970 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Harmony Biosciences during the fourth quarter worth about $41,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Harmony Biosciences during the first quarter worth about $57,000. Finally, KBC Group NV boosted its stake in shares of Harmony Biosciences by 79.9% during the fourth quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after buying an additional 819 shares during the period. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.